¹**Assessing the role of rare pathogenic variants in heart** ²**failure progression by exome sequencing in 8,089 patients**

3

4 Olympe Chazara¹, Marie-Pierre Dubé^{2,3,4}, Quanli Wang¹, Lawrence Middleton¹, Dimitrios Vitsios¹, 5 Anna Walentinsson⁵, Qing-Dong Wang⁶, Kenny M. Hansson⁶, Christopher B. Granger⁷, John 6 Kjekshus⁸, Carolina Haefliger¹, Jean-Claude Tardif^{2,3}, Dirk S. Paul*¹ and Keren Carss*¹

7

¹Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; ²Montreal 9 Heart Institute, Montreal, Canada; ³Université de Montréal, Faculty of Medicine, Department of Medicine, Université de 10 Montréal, Montreal, Canada; ⁴Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada; ⁵ Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; ⁶ 12 Bioscience Cardiovascular, Research and Early 13 Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, 14 Sweden; ⁷Duke Clinical Research Institute, Duke University, Durham, North Carolina; ⁸Department of Cardiology, 15 University of Oslo, Oslo, Norway; *These authors contributed equally.

16 Correspondence: Dirk S. Paul, dirk.paul@astrazeneca.com

- 17
- 18

19 **Abstract**

20

21 Most therapeutic development is targeted at slowing disease progression, often long after the initiating 22 events of disease incidence. Heart failure is a chronic, life-threatening disease and the most common 23 reason for hospital admission in people over 65 years of age. Genetic factors that influence heart 24 failure progression have not yet been identified. We performed an exome-wide association study in 25 8,089 patients with heart failure across two clinical trials, CHARM and CORONA, and one 26 population-based cohort, the UK Biobank. We assessed the genetic determinants of the outcomes 27 'time to cardiovascular death' and 'time to cardiovascular death and/or hospitalisation', identifying 28 seven independent exome-wide-significant associated genes, *FAM221A*, *CUTC*, *IFIT5*, *STIMATE*, 29 *TAS2R20*, *CALB2* and *BLK*. Leveraging public genomic data resources, transcriptomic and pathway 30 analyses, as well as a machine-learning approach, we annotated and prioritised the identified genes for 31 further target validation experiments. Together, these findings advance our understanding of the 32 molecular underpinnings of heart failure progression and reveal putative new candidate therapeutic 33 targets.

Chazara et al.

35 **Introduction**

36

37 Heart failure is a common, chronic health condition with increasing prevalence. In 2017, an estimated 64.3 million people worldwide were living with heart failure¹. Around 2% of adults have heart failure 39 and, in those over the age of 65, the prevalence increases to $6-10\%^{2.5}$. Although survival after 40 diagnosis has improved, death rates remain high, with 5-year survival averaging 50% ⁶. Heart failure is 41 the leading cause of both hospitalization and readmission amongst older adults⁷⁻⁹.

42 Studies have estimated the heritability of heart failure at 26% ¹⁰. Genome-wide association studies 43 (GWAS) have characterised the contribution of common genetic variants to the aetiology of heart 44 . failure¹¹⁻¹³. We recently described the distinct contribution of rare genetic variation to all-cause heart 45 failure in a case-control study¹⁴. We also investigate the genetic differences between heart failure 46 subtypes based on left ventricular ejection fraction (LVEF) and the burden of Mendelian 47 cardiomyopathy variants in these patients. We observed an enrichment of variants typically associated 48 with dilated cardiomyopathy in patients with ischemic heart failure, in particular, protein-truncating 49 variants in the *TTN* gene. Our data supported the notion that genes linked to Mendelian 50 cardiomyopathy could represent therapeutic targets for a broader heart failure indication. Collectively, 51 the vast majority of genetic studies for common chronic diseases such as heart failure have informed 52 on disease incidence, with an unclear relationship to disease progression.

53 Most therapeutic development is targeted at slowing or arresting disease progression in individuals 54 who already have disease. However, studies of disease progression remain challenging, as they require 55 extensive, longitudinal clinical data that require expert curation, such as diagnoses, hospitalisation 56 dates, causes of hospitalisation and death. They also present statistical and computational challenges, 57 as the most well-known approach for analysis of survival (or time-to-event) analysis, the Cox 58 proportional hazards model¹⁵, does not scale well to large datasets¹⁶. Partially overcoming these 59 challenges, powerful and efficient time-to-event analysis frameworks have recently been applied to the 60 UK Biobank¹⁷⁻¹⁹. For heart failure, these studies have mostly focused on time-to-diagnosis phenotypes 61 and/or considered only common genetic variants²⁰.

62 The aim of this study was to identify rare variants associated with heart failure progression. Rare 63 variants have typically larger effects on phenotypes and reveal more direct insights into biology that 64 can be exploited for medicine development²¹. Specifically, the objectives of this study were to (1) 65 perform a survival analysis of heart failure patients to identify genes with an excess or depletion of 66 rare variants in individuals with a detrimental outcome such as shorter time to cardiovascular death; 67 (2) explore how these results can inform the genetic architecture of heart failure progression; and (3) 68 evaluate which of the identified progression-associated candidate genes could present potential 69 candidates for therapeutic development. To address these objectives, we analysed whole-exome 70 sequencing data from patients with heart failure, representing all broad clinical subtypes, from the 71 Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and

Chazara et al.

72 Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials, and heart 73 failure patients from the UK Biobank²²⁻²⁴. All three cohort studies had extensive clinical information 74 available and had been previously studied for heart failure incidence. We applied gene-based 75 collapsing analyses within each study, followed by meta-analysis to discover genes with an excess of 76 rare variants associated with two heart failure outcomes, 'time to cardiovascular death' and 'time to 77 cardiovascular death and/or hospitalisation'.

- 78
- 79

80 **Results**

81

82 **Description of the study cohorts and analytical approach.** In this study, we analysed a total of 83 8,089 heart failure patients: 2,672 from CHARM, 2,776 from CORONA and 2,641 from the UK 84 Biobank. From these 8,089 individuals, 1,328 (16.4%) died of cardiovascular death, and 2,451 85 (30.3%) either died of cardiovascular death or were hospitalised due to heart failure following study 86 entry (**Table 1**, **Figure 1**).

87 First, we analysed the three study cohorts separately to detect rare variants associated with the two 88 outcomes 'time to cardiovascular death' and 'time to cardiovascular death and/or heart failure 89 hospitalisation'. We used gene-level collapsing analyses to classify the genotypes, and Cox 90 proportional hazards regression with Firth's penalized likelihood to analyse each individual's disease 91 progression (**Methods**). In gene-level collapsing analyses, the proportion of cases with a qualifying 92 variant is compared with the proportion of controls with a qualifying variant in each gene. We applied 93 ten different sets of qualifying variant filters (models) (**Methods**). Finally, we used a meta-analysis 94 approach to identify genes with overall evidence of association.

95

96 **Rare-variant analysis for time to cardiovascular death in heart failure patients.** For time to 97 cardiovascular death in heart failure patients, the gene-based collapsing meta-analysis identified five 98 significantly associated genes (p<2x10⁻⁷): *FAM221A* (p=3.85x10⁻⁸, hazard ratio (HR) 5.14), *CUTC* 99 (p=3.90x10⁻⁸, HR 5.13), *IFIT5* (p=4.77x10⁻⁸, HR 4.77), *STIMATE* (p=7.68x10⁻⁸, HR 4.39) and 100 *TAS2R20* ($p=2.57x10^{-7}$, HR 3.93) (**Table 2**, **Figure 2A-E**). The meta-analysis for these five genes was 101 based on the survival analysis of the three contributing studies, with at least five carriers per study. 102 None of the single-study analysis results for time to cardiovascular death in heart failure patients 103 passed the significance threshold of $p \le 2x10^{-7}$, demonstrating the power of meta-analysis for this 104 phenotype to discover novel rare-variant based signals (**Supplementary Tables 1-3**). The meta-105 analysis also revealed a significant association for *CHRNA9* ($p=1.89x10^{-7}$, HR 4.72) but the supporting 106 survival analysis in CHARM was violating the proportionality hazard assumption; therefore, we did 107 not report this association result.

Chazara et al.

108 We assessed the distributions of the qualifying variants along the length of each of the five 109 identified genes (**Figure 3A-E**). We found that the observed associations with the lowest p-values 110 were driven by at least eight variants per gene, and were evenly distributed across the length of the 111 gene sequence (**Supplementary Table 4**).

112

113 **Rare-variant analysis for the composite of time to cardiovascular death and/or heart failure** 114 **hospitalisation.** For the second of the two outcomes investigates, the composite of time to 115 cardiovascular death and/or heart failure hospitalisation, the gene-based collapsing meta-analysis 116 identified two significantly associated genes $(p<2x10^{-7})$: *CALB2* ($p=4.82x10^{-9}$, HR 4.47) and *BLK* (p=5.46x10-8 117 , HR 6.91) (**Table 2**, **Figure 2F-G**). While the meta-analysis for *CALB2* result was based 118 on the survival analysis of the three studies, with at least five carriers per study, the result for *BLK* was 119 only based on the CORONA and UK Biobank studies, as there was only one carrier for *BLK* in 120 CHARM. The proportionality hazard assumption was not met for *CALB2* in CHARM, but after 121 removal of the study from the analysis, the meta-analysis result remained significant ($p=2.15x10^{-8}$, HR 122 5.48).

123 We report one significant result from the single-study analysis for time to cardiovascular death 124 and/or heart failure hospitalisation in heart failure patients: *RAD54L* in the flexible non-synonymous 125 model in CHARM (p=6.64x10⁻⁸, HR 3.96; **Supplementary Tables 5-7**). *RAD54L* in the 126 corresponding analysis in CORONA and the UK Biobank was not significantly associated with heart 127 failure progression (p>0.1 and number of qualifying variant carriers >30 in both cohorts). Different 128 genetic architecture across the studies could reflect underlying clinical differences, due to the differing 129 recruitment criteria employed.

130 We assessed the distributions of the qualifying variants along the length of the identified genes 131 (**Figure 3F-G**) and found that the observed associations with the lowest p-values were driven by 13 132 variants for the *CALB2* gene and seven variants for *BLK* (**Supplementary Table 4**). We found these 133 variants to be evenly distributed across the length of the gene sequence (**Supplementary Table 4**).

134

135 **Orthogonal genetic evidence in support of rare-variant meta-analysis results.** To investigate to 136 what extent the discovered genes from our rare-variant meta-analyses are associated with related 137 phenotypes in complementary data sources, we annotated the genes with orthogonal genetic evidence: 138 (1) curated common-variant association studies for cardiovascular diseases from the Cardiovascular 139 Disease Knowledge Portal (https://cvd.hugeamp.org/); (2) known Mendelian cardiomyopathy-causing 140 genes; and (3) a gene prioritisation method that leverages external data sources using a machine-141 learning (ML) approach (Mantis-ML)²⁵.

142 We collated the curated evidence from published GWAS from the Cardiovascular Disease 143 Knowledge Portal for the seven candidate genes from the meta-analysis for both tested outcomes 144 (**Table 3**). We found genome-wide significant associations with cardiovascular traits in the genomic

Chazara et al.

145 regions of *CUTC*, *IFIT5*, *STIMATE*, *CALB2* and *BLK*. There were also genome-wide significant 146 associations with lipids traits in the regions of *CUTC*, *STIMATE*, *CALB2* and *BLK*, and with 147 anthropometric traits in the regions of *FAM211A*, *CUTC*, *STIMATE*, *CALB2* and *BLK* (**Table 3A**). A 148 limitation of this comparison is that a majority of the reported associations had the UK Biobank 149 included in the meta-analysis, and the relationship between the GWAS index variants and causal genes 150 at the loci requires further experimental confirmation. However, we did not detect genome-wide 151 significant associations in either the region or the gene for the most relevant reported phenotypes, i.e., 152 heart failure, non-ischemic cardiomyopathy, atrial fibrillation, any cardiovascular disease, myocardial infarction, and hypertension. Only *IFIT5*, *STIMATE* and *CALB2* had suggestive associations (p<1x10⁻ ⁵ 154) for any cardiovascular disease (*IFIT5* and *STIMATE*) or hypertension (*STIMATE* and *CALB2*) **155** (**Table 3B**). The lowest p-values observed in the *CUTC* region were for heart rate ($p=2.73x10^{-9}$), 156 height (p=1.80x10⁻²⁸) and atrial fibrillation (p=1.79x10⁻⁴) (**Table 3B**). 157 Among the known rare or low-frequency variants in cardiomyopathy-causing genes previously

158 identified such as *TTN*, *MYH7* and *MYBPC3* for heart failure incidence and *LMNA* and *LAMP2* for 159 heart failure progression, we observed a non-significant association of ultra-rare variants in *MYBPC3* 160 with time to cardiovascular death ($p=2.05x10^{-6}$, HR 4.38), but not for the other reported genes. Most of 161 these cardiomyopathy-causing genes had a very low number of pathogenic variant carriers, making 162 interpretation challenging. However, *TTN* pathogenic variants were more frequent, indicating that *TTN* 163 might be specifically associated with heart failure incidence rather than progression, which has been 164 reported previously²⁶.

165 Finally, we applied Mantis-ml, a ML framework leveraging publicly available gene annotation data 166 to prioritise disease-gene associations²⁵. We used this orthogonal method to investigate the extent to 167 which the significant genes from our rare-variant meta-analyses $(p<0.01)$ are similar to genes known, 168 or predicted with high confidence, to be associated with relevant phenotypes (i.e., the top-ranked 169 genes from Mantis-ml conditioned on heart failure or cardiomyopathy). These similarities were 170 quantified using a step-wise hypergeometric test (**Methods**). For both outcomes, we found the overlap 171 in relevant phenotypes to be greater for the qualifying variant models that capture functional variants 172 than for the synonymous negative control model (**Supplementary Figs. 1A, 1B**). In addition, 173 collapsing the 33 heart failure/cardiomyopathy disease classes available to a single metric (i.e., taking 174 either the maximum or the AUC), we found significantly superior performance of the pooled 175 qualifying variant model compared to the synonymous model for both, time to cardiovascular death 176 ($p_{max} = 1.6x10^{-5}$ and $p_{AUC} = 8.0x10^{-4}$) and time to cardiovascular death and/or hospitalisation for heart 177 failure ($p_{max} = 5.1 \times 10^{-5}$ and $p_{AUC} = 3.9 \times 10^{-4}$) (**Supplementary Fig. 1C**). Taken together, these results 178 showed that the features of the most significantly associated genes from our meta-analysis share 179 similarities with the features of genes already known, or strongly predicted, to be associated with 180 relevant phenotypes, supporting our genetic data.

Chazara et al.

182 **Expression analysis in heart tissues aids gene prioritisation for further validation.** Next, we 183 assessed the expression patterns of the candidate causal genes underlying the genetic associations for 184 heart failure progression. Normalized gene expression data collected by the GTEx Project²⁷ were 185 interrogated for the seven candidates genes from the meta-analysis for both tested outcomes (**Table 2**). 186 We used the 54 different tissues sampled by GTEx as well as a subset of 16 cardiovascular tissues.

187 The overall tissue expression analysis revealed that *CUTC*, *STIMATE* and *IFIT5* are expressed in 188 almost all tissues analysed; *CALB2* and *BLK* are expressed in multiple tissues but not all; and 189 *TAS2R20* and *FAM221A* have comparatively low expression across all tissues analysed 190 (**Supplementary Fig. 2A**). *CUTC* was the gene most strongly expressed in the heart. In cardiovascular 191 tissue, a similar gene grouping was observed, with *CUTC* highest in skeletal muscle, *CALB2* in 192 adipose, and *BLK* in whole blood and spleen tissues (**Supplementary Fig. 2B**).

193 Next, we analysed differential expression of the candidate genes in tissues from ventricular 194 myocardial biopsies in heart failure with preserved/reduced ejection fraction (HFpEF/HFrEF), 195 (idiopathic) dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), ischemic 196 cardiomyopathy (ICM), and controls from three separate public transcriptomics studies (**Figure 4**, **Supplementary Table 8**) ²⁸ 197 . *CUTC*, *IFIT5*, *TAS2R20*, *FAM221A* and *BLK* showed significant 198 differential expression between the healthy and diseased heart. Among these, *CUTC* was most 199 consistently dysregulated, being downregulated across studies and heart failure aetiologies. *TAS2R20* 200 and *BLK* have low expression in the heart, making the results challenging to interpret. *FAM221A*, 201 *IFIT5* and *TAS2R20* showed significant differential expression between HFpEF vs HFrEF patients in 202 the right ventricle (**Figure 4**, **Supplementary Fig. 2**, **Supplementary Table 8**).

203 Taken together, based on all transcriptional datasets, we highlight *CUTC* as a potential therapeutic 204 target for heart failure progression that warrants further experimental validation and assessment.

205

206 **Functional enrichment analysis identifies molecular functions and pathways of candidate genes.**

207 To identify potential molecular functions and pathways underlying the genetic associations, we 208 performed a gene ontology analysis of the candidate genes. We tested 1298 unique genes ranked by 209 their lowest fixed model p-value across the ten non-synonymous collapsing analysis models from the 210 time to cardiovascular death meta-analysis. We found enrichment (adjusted p<0.05) for the following 211 molecular functions: adenyl ribonucleotide binding $(GO:0032559, p=8.91x10^{-4})$; adenyl nucleotide 212 binding (GO:0030554, p=1.43x10⁻³); lamin binding (GO:0005521, p=1.49x10⁻³); among others

```
213 (Supplementary Fig. 3A, Supplementary Table 9).
```
214 We also performed the analysis for the 956 unique genes from the time to cardiovascular death 215 and/or hospitalisation for heart failure meta-analysis. This analysis revealed enrichment for the 216 following molecular functions and biological pathways: ion binding (GO:0043167, $p=3.42x10^{-3}$); 217 glycine, serine and threonine metabolism (KEGG:00260, $p=4.17x10^{-3}$); among others 218 (**Supplementary Fig. 3B**, **Supplementary Table 9**).

Chazara et al.

219

220 **Discussion**

221

222 The identification of determinants of disease progression is critical for drug development, as most 223 clinical trials assess the efficacy and safety of treatments that slow or arrest disease progression in 224 patients with disease or prevent secondary events in specific patient groups. However, in contrast to 225 the relatively large number of genetic studies on the incidence of common chronic diseases, including 226 heart failure, there are few published studies investigating the genetic basis of disease progression.

227 In our study, we implemented a survival analysis for rare variants based on collapsing analysis and 228 Cox proportional hazards regression with Firth's penalized likelihood. We analysed the whole-exome 229 sequencing data of 8,089 heart failure patients from three clinically well-defined studies: two clinical 230 trials, CHARM and CORONA, and one population-based study: the UK Biobank. We performed 231 meta-analysis and reported results found in at least two studies and supported by at least five carriers 232 per study. We report seven genes not previously associated with heart failure progression with hazard 233 ratios between 3.93 and 6.91. Specifically, we identified five candidate genes for cardiovascular death 234 risk in heart failure patients: *FAM221A*, *CUTC*, *IFIT5*, *STIMATE* and *TAS2R20*, and two candidate 235 genes for the composite of cardiovascular death and/or heart failure hospitalisation risk in heart failure 236 patients: *CALB2* and *BLK*.

237 Importantly, none of these identified candidate gene loci have previously been associated with 238 heart incidence through common-variant association studies, suggesting distinct genetic aetiology for 239 heart failure progression compared to incidence. However, when evaluating the prior evidence of 240 association with disease incidence, we found that all but two candidate gene loci (i.e., *FAM221A* and 241 *TAS2R20*) harboured genome-wide significant, common-variant associations with cardiovascular 242 traits, including heart rate, ascending aorta diameter and blood pressure.

243 We showed that several of the candidate genes are expressed in relevant cardiovascular tissues. In 244 particular, *CUTC* is expressed strongly in heart tissues. Using heart single-cell RNA-seq data, we 245 demonstrated that *CUTC* is expressed by all cardiac cell types with highest fractional expression in 246 cardiomyocytes **(Supplementary Fig. 4**). Further, we demonstrated differential expression of five out 247 of seven candidate genes between diseased and healthy hearts and/or between heart failure subtypes.

248 Finally, ML-based enrichment analysis supported our gene ranking from the meta-analysis, 249 especially for the cardiovascular death outcome, as indicated by step-wise hypergeometric analyses.

250 Functional enrichment analysis highlighted known pathways in cardiovascular disease, such as lamin

251 binding (enrichment supported by *SUN1*, *TMEM201*, *SUN2*, *SYNE1* and *PLCB1*), and novel pathways,

252 such as glycine, serine and threonine metabolism (supported by *GLDC*, *PGAM1* and *ALDH7A1*)^{29,30}.

253 *CUTC* was the only gene that showed an association with both tested endpoints, as well as strong 254 expression in the heart and differential expression between diseased and healthy heart tissues. *CUTC* 255 encodes a member of the CUT family of copper transporters that are associated with copper

Chazara et al.

256 homeostasis and involved in the uptake, storage, delivery and efflux of copper³¹⁻³³. Defective copper 257 metabolism has been linked to various cardiovascular diseases, including heart failure. Mutations in 258 genes encoding copper chaperones/transporters associate with cardiac disease in humans and mice 34 . 259 Notably, the ongoing TRACER-HF trial (NCT03875183) evaluates the effects of a copper-binding 260 agent INL1 in patients with HFrEF. INL1 is hypothesized to redistribute copper from high-261 concentration gradient (e.g., the circulation) to copper-depleted tissues (e.g., ischemic myocardial 262 tissue), inducing heart regeneration. Although the exact function of CUTC remains to be determined, 263 it has been suggested that it might act as an enzyme with Cu(I) as a cofactor rather than a copper 264 transporter³¹. Moreover, CUTC participates in cardiac conduction and ion channel transport pathways 265 based on the PathCards database (https://pathcards.genecards.org) and our co-expression network 266 analysis suggested a role in muscle physiology and mitochondrial function (**Supplementary Fig. 4**). 267 These pathways are all highly relevant biofunctions in heart failure pathophysiology. Our tractability 268 assessment further revealed that CUTC contains a high-quality ligand pocket and is predicted 269 druggable using small molecules (**Supplementary Table 10**). Taken together, *CUTC* may represent 270 an attractive new candidate therapeutic target in heart failure.

271 Of note, alternative *CUTC* transcripts overlap *COX15*, encoding the Cytochrome C Oxidase 272 Assembly Homolog. Despite a larger number of rare variant carriers than *CUTC*, *COX15* was not 273 significantly associated with either cardiovascular death or the composite of cardiovascular death 274 and/or heart failure hospitalisation in our analyses (**Supplementary Tables 11, 12**). Diseases 275 associated with *COX15* include Mitochondrial Complex IV Deficiency, Nuclear Type 6 and Fatal 276 Infantile Cardioencephalomyopathy Due To Cytochrome C Oxidase Deficiency. It has been proposed 277 that *CUTC* and *COX15* functions in partnership as they share a bidirectional promoter³⁵.

278 *STIMATE* and *CALB2* are involved in calcium binding, signalling or channel activity. Calcium 279 pathways are fundamental for electrical signalling in the heart³⁶. Several known mechanisms of 280 cardiac pathologies are underlined by calcium channels³⁶. A major class of drug targets already exist 281 for calcium channel regulation^{37,38}. Calcium antagonists have been used to treat ischemia, a common 282 cause of heart failure³⁹. *IFIT5* and *BLK*, are involved in immune system function. It is established that 283 inflammation plays an important role in chronic heart failure, after myocardial infarction or other 284 myocardial damage, and heart failure is associated with circulating inflammatory cytokines that can 285 predict clinical outcomes⁴⁰. Whether inflammation plays a causal role remains to be established⁴¹. A 286 number of taste receptors including *TAS2R20* are expressed in human heart and the role of these 287 receptor in cardiac physiology and pathophysiology is not well understood yet⁴². It is notable that 288 *TAS2R20* RNA expression is significantly increased in the myocardium in HFpEF patients but not in 289 HFrEF patients, suggesting that *TAS2R20* may have a specific role in HFpEF.

290 In our meta-analysis, we did not discover any significantly associated protective genes. Such genes 291 would be particularly promising for drug development as a protective effect of loss of function mimics 292 the therapeutic inhibition of a drug. We observed previously in genetic analyses of heart failure

Chazara et al.

293 incidence that detrimental association of rare variants are more prevalent than protective associations,

294 because they are enriched for loss-of-function variants 14 .

295 We acknowledge that our study had limitations. Due to the paucity of exome-wide investigation of 296 the role of rare variants in heart failure progression, we were currently unable to replicate our findings 297 in an independent study cohort. More collaborative research is needed to address this limitation of our 298 study, e.g., through the HERMES consortium that aims to assess the contribution of common genetic 299 variants to heart failure progression²⁰. Further, we note that the definition of heart failure amongst the 300 cases was heterogeneous, for example, with respect to the presence or absence of cardiomyopathy, and 301 different LVEF categories (HFrEF vs HFpEF). Due to the study of rare variants, stratifying patients 302 according to phenotypic subtypes would have substantially reduced power. Additionally, for heart 303 failure incidence and cardiomyopathy-associated rare variants, we previously detected some 304 overlapping genetic architecture between heart failure subtypes¹⁴, supporting our combined approach 305 in this study. Future larger studies would facilitate stratified analyses. Finally, our study focussed on 306 individuals of European ancestry because there are insufficient numbers of patients of other ancestries. 307 Further studies are needed to replicate our findings in other ancestry groups. 308 In conclusion, by rare-variant collapsing meta-analysis, we have identified seven candidate genes 309 significantly associated with heart failure progression: *FAM221A, CUTC, IFIT5, STIMATE, TAS2R20,* 310 *CALB2* and *BLK*. Pending replication, several of these genes could represent promising drug targets

311 for heart failure, as supported by their tissue expression and function.

Chazara et al.

313 **Methods**

314

315 **Ethics statement.** Sites participating in the CHARM and CORONA studies received approval from 316 local ethics committees for their conduct^{22,23}. Only patients who gave written informed consent for 317 genetic analysis and for whom a DNA sample was available were included in the present study. The 318 present study was performed in accordance with the policies on bioethics and human biologic samples 319 of AstraZeneca. The protocols for UK Biobank are overseen by the UK Biobank Ethics Advisory

- 320 Committee. For more information see https://www.ukbiobank.ac.uk/ethics/.
- 321

322 **CHARM and CORONA studies.** The CHARM programme enrolled heart failure patients of >18 323 years of age into three distinct trials and randomly assigned them to receive candesartan or placebo: 324 patients with LVEF >40% (CHARM Preserved; NCT00634712); patients with LVEF $\leq 40\%$ and 325 treated with angiotensin converting enzyme inhibitor (CHARM Added; NCT00634309); and patients 326 with LVEF \leq 40% and intolerant to angiotensin-converting enzyme inhibitor treatment (CHARM Alternative; NCT00634400 $)^{22}$. In the CHARM study, heart failure cause could be defined as ischemic, 328 idiopathic, hypertensive or other causes²². The CORONA study enrolled patients of >60 years of age 329 with chronic heart failure of ischemic cause and a LVEF \leq 40% and randomly assigned them to 330 receive rosuvastatin or placebo $(NCT00206310)^{23}$. An overview of the patient characteristics of the 331 trials is provided in **Table 1**.

332 In the CHARM and CORONA trials, the same two endpoints (i.e., cardiovascular death and a 333 composite of cardiovascular death and/or heart failure hospitalisation) were defined by the clinical 334 teams. For CHARM, cardiovascular death or unplanned admission to hospital for the management of 335 worsening congestive heart failure was the primary outcome for the trial. All deaths were classified as 336 cardiovascular unless an unequivocal non-cardiovascular cause was established. An heart failure 337 hospital admission was defined as an admission to hospital because of heart failure with evidence of 338 worsening heart failure²². For CORONA, the primary outcome was death from cardiovascular causes, 339 nonfatal myocardial infarction, or nonfatal stroke. Deaths were classified as due to cardiovascular 340 causes unless a definite non-cardiovascular reason was identified. Hospitalization for heart failure 341 required documentation that worsening heart failure was the principal reason for hospitalization²³.

342

343 **UK Biobank.** The UK Biobank is a large prospective cohort study with 500,000 participants aged 40 to 69 years recruited from the general population in the United Kingdom²⁴. The UK Biobank ICD10 345 codes (International Statistical Classification of Diseases and Related Health Problems, Tenth 346 Revision codes) were interrogated for the following heart failure phenotypes: I11.0, I13.0, I13.2, 347 I25.5, I42.0, I42.5, I42.8, I42.9 and $150.x^{11}$. Overall, 11,076 individuals with at least one primary or 348 secondary hospital in-patient diagnoses code (Data-Field ID 41270), and/or at least one underlying 349 (primary) cause of death in the death register (Data-Field ID 40001) in those categories, were

Chazara et al.

350 considered as heart failure patients. In order to more closely match a clinical study design, only cases 351 with heart failure diagnosis codes dated prior to recruitment were included in the analyses. 352 Measurements of LVEF were not performed for the UK Biobank patients, as it was only available for 353 a small number of individuals randomly selected from the biobank (**Table 1**).

354 For our analysis, we defined two endpoints: cardiovascular death (CVD) and a composite of 355 cardiovascular death and/or heart failure hospitalisation (CVD_HFHOSP). In the UK Biobank, 356 cardiovascular death was defined as a primary cause of death (Data-Field ID 40001) with any ICD10 357 codes in the Chapter IX (Diseases of the circulatory system), which correspond to I00-I99 codes. 358 Heart failure hospitalisation was defined as a hospitalisation at least 28 days after the first diagnosis, 359 with the same code used for the heart failure patient definition. To match the modelling approach used 360 in the clinical studies, the date of recruitment was used to calculate the time to event. The end of 361 follow-up was considered to be the date of the last major UK Biobank update (01/09/2019).

362

363 **Exome-sequencing.** For CHARM, CORONA and UK Biobank, exomes were captured with the IDT 364 xGen Exome Research Panel V1.0 (Integrated DNA Technologies, Coralville, IA, USA) and 365 sequenced according to standard protocols on Illumina's NovaSeq 6000 (Illumina, San Diego, CA, 366 USA) platform. Exome sequencing for CHARM and CORONA was performed using 150bp paired-367 end reads at the Institute for Genomic Medicine at the Columbia University Medical Center, as 368 previously described¹⁴. Exome sequencing for the UK Biobank using 75-bp paired-end reads and 369 initial sample-level QC the UK Biobank was performed at Regeneron Pharmaceuticals, as previously 370 described^{14,43,44}. Quality control of the genetic data performed by Regeneron included sex discordance, 371 contamination, unresolved duplicated sequences and discordance with microarray genotyping data⁴⁵.

372 Sequence data from all three studies was processed through the AstraZeneca's Centre for 373 Genomics Research bioinformatics pipeline using a custom-built Amazon Web Services cloud 374 compute platform running Illumina DRAGEN Bio-IT Platform Germline Pipeline v3.0.7. The reads 375 were aligned to the GRCh38 genome reference, followed by single-nucleotide variant (SNV) and indel 376 calling. SNVs and indels were first annotated using SnpEFF v4.34 against Ensembl Build 38.92. 377 Variants were then annotated using the Genome Aggregation Database (gnomAD) minor allele 378 frequencies (gnomAD v2.1.1 mapped to GRCh38), missense tolerance ratio (MTR) and REVEL 379 scores⁴⁶⁻⁴⁸.

380

381 **Sample and variant quality control (QC).** The pre-QC dataset consisted of 3,090 CHARM, 2,906 382 CORONA and 2,868 UK Biobank participants. The following samples were removed: discordance 383 between self-reported sex and genomic predicted sex based on X:Y coverage ratio; >4% 384 contamination according to VerifyBamID v1.0.5; <95% of CCDS (release 22) bases covered with at 385 least 10-fold coverage; related (up to third degree with KING v2.2.3), probability of European 386 Ancestry <0.98 (<0.99 for UK Biobank) based on PEDDY v0.4.2 predictions; and individuals within

Chazara et al.

387 four standard deviations of principal components 1-4 (**Supplementary Table 13**)⁴⁹⁻⁵¹. The final 388 filtered dataset for analysis consisted of 2,672 CHARM, 2,776 CORONA and 2,641 UK Biobank 389 samples (**Figure 1**, **Table 1**).

390

391 **Gene-level collapsing analyses.** We first performed, in the three cohorts separately, gene-based 392 collapsing analyses to identify patients carrying at least one qualifying variant in each protein-coding 393 gene. A qualifying variant is defined as a variant that passes certain filter criteria specific to each 394 genetic model. **Supplementary Table 14** summarises the genetic models used for the analyses. We 395 analysed ten non-synonymous models (nine of which are dominant and one recessive), plus an 396 additional synonymous variant model as a negative control⁵².

397 The data was modelled using Cox proportional hazards regression with Firth's penalized 398 likelihood, which provides a solution to the non-convergence of the likelihood function, more f_1 frequently observed with rare-variant analysis: coxph $f_1^{53,54}$. Genotypes were encoded as binary variable 400 after the first step of collapsing analysis. The coxphf method has been shown to be appropriate for 401 genome-wide time-to-event analysis, both in terms of controlling type I error rates, and power for 402 variants with low minor allele frequency¹⁸. In CHARM and CORONA, age at recruitment, sex and 403 treatment arm were used as covariates in all analyses. The coxphf default of confidence intervals and 404 tests based on the profile penalized log likelihood was used. In the UK Biobank, age at recruitment 405 (Data-Field ID 21022) and sex (Data-Field 22001) were used as covariates in all analyses. For the 406 collapsing survival analysis, the Bonferroni multiplicity adjusted threshold was set at p=2.7x10⁻⁷ (α = 407 [0.05 / (18,500 genes * 10 non-synonymous models)]). This threshold was supported by permuting the 408 data using R perm function (n=1) within the synonymous model, comparing with observed p-values 409 with quantile-quantile plots and estimating the genomic inflation factor λ (**Supplementary Fig. 5**). 410 The proportionality of hazards assumption was examined for the top genes by using the Schoenfeld 411 residuals against the transformed time.

412

413 **Meta-analysis.** We conducted a meta-analysis using PLINK v1.90 on the beta-values and standard 414 errors extracted from the coxphf results. We computed both fixed and random effect meta-analysis 415 models, and we only reported results supported by at least five carriers in each study. We computed 416 both fixed and random effects meta-analysis models and reported random effects results with a 417 heterogeneity index $I^2 > 40$. Consistent with the survival analysis, the meta-analysis Bonferroni 418 multiplicity adjusted threshold was set at $p \le 2.7x10^{-7}$ ($\alpha = [0.05 / (18,500 \text{ genes} * 10 \text{ non-synonymous}])$ 419 models)]). Quantile-quantile plots for the meta-analysis were generated with (permutation-based) 420 expected p-values from data permuted prior to the collapsing survival analysis using the R perm 421 function (n=1) (**Supplementary Figs. 6A, 6B**).

Chazara et al.

423 **Sensitivity analysis.** Analyses were conducted with additional covariates such as BMI and prior 424 diabetes to assess the robustness of results when relevant for the genes with significant results 425 ($p<2.7x10⁻⁷$) in the meta-analysis of CHARM, CORONA and the UK Biobank for both tested 426 outcomes. Detailed clinical information supporting the analyses are reported in **Table 1**. Sensitivity 427 analyses did not change the observed results (**Supplementary Table 15**).

428

429 **RNA expression.** We interrogated median TPM-normalized gene expression for 54 tissues sampled in 948 donors provided by GTEx $v8^{27}$. We defined a subset of 16 cardiovascular tissues as follows: 431 Adipose - Subcutaneous, Adipose - Visceral (Omentum), Adrenal Gland, Artery - Aorta, Artery - 432 Coronary, Artery - Tibial, Heart - Atrial Appendage, Heart - Left Ventricle, Kidney - Cortex, Kidney - 433 Medulla, Liver, Muscle - Skeletal, Pancreas, Spleen, Thyroid, Whole Blood. 434 In addition, we extracted and analysed data from three published myocardial transcriptomic

435 analyses: (1) HFpEF (n=41), HFrEF (n=30) and controls (n=24); (2) DCM (n=166), HCM (n=28) and 436 controls (n=166) (GSE141910, The Myocardial Applied Genomics Network; 437 https://www.med.upenn.edu/magnet/); and (3) idiopathic DCM (n=82), ICM (n=95) and controls 438 $(n=136)$ (GSE57338)⁵⁵.

439

440 **Annotation with GWAS data.** For the genes most significantly associated with heart failure 441 progression, we compiled genetic evidence from the curated GWAS results of external studies 442 available in the Cardiovascular Disease Knowledge Portal (https://cvd.hugeamp.org/). First, we listed 443 the association with the lowest genome-wide significant p-values in the region, where associations are 444 clumped by linkage disequilibrium and classified into three phenotypes group: cardiovascular, lipids 445 and anthropometric. Then, we used the Cardiovascular Disease Knowledge Portal Genomic Region 446 Miner tool to extract the lowest variant associations across each region or in the gene for the following 447 six phenotypes: heart failure, non-ischemic cardiomyopathy, atrial fibrillation, any cardiovascular 448 disease, myocardial infarction, or hypertension.

449

450 **Step-wise hypergeometric enrichment analysis with Mantis-ml.** Mantis-ml is a method for gene 451 prioritisation, leveraging publicly available gene annotation data from multiple resources to derive 452 genetic association scores for a user-specified disease²⁵. Harnessing data from resources such as 453 OMIM, ExAC, Essential Mouse Genes, GnomAD, MSigDB, GTEx and genic-intolerance scores 454 (RVIS and MTR) among others, we used this tool to assess to what extent the most significant genes 455 from the meta-analysis are similar to genes known to be associated with heart failure or 456 cardiomyopathy.

457 We performed a step-wise hypergeometric test between the study-ranked list of genes with a fixed 458 p-value<0.01 for one of the outcomes (**Supplementary Tables 11, 12**) and 18,626 genes pre-ranked 459 by their Mantis-ml association scores for 33 diseases containing either 'heart failure' or

460 'cardiomyopathy' (i.e., 26 from OpenTargets, four from HPO, three from Genomics England). An 461 overview of these diseases is provided in **Supplementary Table 16**. The resulting step-wise 462 hypergeometric curves are shown in **Supplementary Fig. 1**.

463 This test quantifies the overlap between the list of genes identify in this heart failure progression 464 study and the list of genes ranked according to independent data sources by Mantis-ml. The p-values 465 generated are converted to Phred scores. Enrichment performance were assessed and p-values 466 obtained using the one-sided Mann-Whitney U test.

467

468 **Gene ontology enrichment analysis.** A functional enrichment analysis was performed using 469 g:Profiler for the same lists of genes ordered on fixed p-value as done for the annotation with Mantis-470 ml, i.e., the genes with a fixed effect p-value<0.01 for each of the outcomes (**Supplementary Tables** 471 **11, 12**⁵⁶. The data sources tested were Gene Ontology (GO, molecular function, cellular component, 472 biological process), KEGG and miRTarBase. The background set of gene used to compute the 473 functional enrichment was the 18,948 genes list from the Consensus Coding Sequence (CCDS, release 474 22), over annotated genes. Multiple testing correction for p-values was computed by applying the 475 default g:SCS method.

476

477 **Tractability assessment.** For the genes most significantly associated with heart failure progression, 478 we assessed the amenability to intervention by different drug modalities, including small molecules, 479 antibodies, PROTAC and others, using the Open Target Platform (https://platform.opentargets.org/). 480 The genes were categorized based on 'buckets' representing different levels of tractability, ranging 481 from high confidence (lower number) to uncertain tractability (higher number), as previously 482 described⁵⁷. In addition, genes were also classified according to their 'target development level' (TDL) 483 into either of four classes (i.e., Tclin, Tchem, Tbio or Tdark) using the Target Central Resource 484 Database (TCRD, http://juniper.health.unm.edu/tcrd/). In brief, Tclin are proteins through which 485 approved drugs act (i.e., mode-of-action drug targets); Tchem are proteins known to bind small 486 molecules with high potency; Tbio are proteins with well-studied biology, having a fractional 487 publication count above 5; and Tdark are understudied proteins that do not meet criteria for the above 488 3 categories, respectively (**Supplementary Table 10**).

489

490 **Co-expression network analysis.** To further explore the *CUTC* function, we performed co-expression 491 analysis using GeneNetwork v2.0 (https://www.genenetwork.nl/), which predicts pathway and human 492 phenotype associations using 31,499 public human RNA-seq samples (**Supplementary Fig. 4**).⁵⁸

- 493
- 494

495 **Data availability**

Chazara et al.

649 **Acknowledgments**

650

651 We thank the participants and investigators of the UK Biobank study who made this work possible 652 (Resource Application Number 26041). We thank the UKB Exome Sequencing Consortium (UKB-653 ESC) members AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, 654 Pfizer, Regeneron and Takeda for funding the generation of the data, and the Regeneron Genetics 655 Center for completing the sequencing and initial quality control of the exome sequencing data. We 656 acknowledge the AstraZeneca Centre for Genomics Research Analytics and Informatics team for 657 processing and analysis of sequencing data. We thank all the study participants for contributing to this 658 effort and the CHARM and CORONA co-investigators. Finally, we thank Sri Deevi and Dorota 659 Matelska from the AstraZeneca Centre for Genomics Research for their support, for which we are 660 grateful. M.-P.D. is funded by the Canada Research Chairs Program and by the Health Collaboration 661 Acceleration Fund from the Government of Quebec. J.C.T. holds the Canada Research Chair in 662 personalized and translational medicine and the Université de Montréal endowed research chair in 663 atherosclerosis. 664

665

666 **Author Contributions Statement**

667

668 O.C., M-P.D., C.H., J-C.T., D.S.P. and K.C. conceived and designed the study. O.C., Q.W., L.M. and 669 A.W. performed the statistical and computational analyses. M-P.D., D.V., D.S.P. and K.C. supervised 670 the analyses. M-P.D., C.B.G, J.K., C.H., J-C.T., D.S.P. and K.C. participated in the acquisition of the 671 data. O.C., M-P.D., Q.W., L.M., D.V., A.W., Q-D.W., K.M.H., C.B.G, J.K., C.H., J-C.T., D.S.P. and 672 K.C. participated in the data interpretation. O.C., M-P.D., L.M., A.W., J-C.T., D.S.P. and K.C. wrote 673 the initial draft of the manuscript. All authors contributed to the revision of the first draft. All authors 674 approved the final version of the manuscript.

675 676

677 **Competing Interests Statement**

678

679 O.C., Q.W., L.M., D.V., A.W., Q.-D.W., K.M.H., C.H., D.S.P. and K.C. report personal fees from 680 AstraZeneca during the conduct of the study. Q.W., C.H. and D.S.P. are stockholders of AstraZeneca. 681 M.-P.D. reports personal fees and minor equity interest from Dalcor, other from AstraZeneca, 682 GlaxoSmithKline, Pfizer, Servier, Sanofi. J.C.T. reports a grant from AstraZeneca for the conduct of 683 the study; other grants from AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis,

684 Pfizer and RegenXBio; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals,

Chazara et al.

685 Pendopharm and Pfizer; minor equity interest in DalCor Pharmaceuticals. J.C.T. is author on patents 686 "Methods of treating a coronavirus infection using Colchicine and Methods of treating a coronavirus 687 infection using Colchicine" pending and a patent "Early administration of low-dose colchicine after 688 myocardial infarction" pending assigned to the Montreal Heart Institute. M.-P.D. and J.C.T. are 689 authors on a patent "Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk 690 of Cardiovascular Events" issued to Dalcor, no royalties received, a patent "Genetic Markers for 691 Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent" issued to 692 Dalcor, no royalties received, and a patent "Methods for using low dose colchicine after myocardial 693 infarction", assigned to the Montreal Heart Institute. J.C.T. has waived his rights in colchicine patents 694 and does not stand to gain financially. C.B.G. reports personal fees from AbbVie, Bayer, Boston 695 Scientific, CeleCor, Correvio, Espero BioPharma, Medscape, Medtronic, Merck, National Institutes of 696 Health, Novo Nordisk, Rhoshan and Roche; grants from Akros, Apple, AstraZeneca, Daiichi Sankyo, 697 US Food and Drug Administration, GlaxoSmithKline and Medtronic Foundation; grants and personal 698 fees from Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Pfizer; and other 699 support from Duke Clinical Research Institute outside the submitted work. Funding for the exome 700 sequencing in the CHARM, CORONA and UK Biobank studies was provided fully or partially by 701 AstraZeneca.

Chazara et al.

703 **Tables**

705 **Table 1. Characteristics of patients included in the analysis.**

706

707

708 *LVEF only available for 66 UK Biobank individuals. BMI: body mass index; CV: cardiovascular; HF: heart

709 failure; LVEF: left ventricular ejection fraction; N: number of patients; NA: not available; SD: standard

710 deviation.

⁷⁰⁴

Table 2. Gene-based collapsing meta-analysis results for 'time to cardiovascular death' (top) or 'time to cardiovascular death and/or hospitalisation for heart failure' (bottom).

Fixed-effects meta-analysis p-value<2.7x10⁻⁷; *genetic model details in **Supplementary Table 14**; **filtered on I²≤40; [†]filtered on carrier count ≥5 from input (a posteriori); P: Fixed-effects meta-analysis p-value; HR: hazard ratio; CI: confidence interval; SE: standard error; Q: Cochran's Q p-value testing for heterogeneity⁵⁹; I²: percentage of variation across studies that is due to heterogeneity rather than chance⁶⁰; CHARM/CORON/UK Biobank P: coxphf p-value for CHARM/CORONA/UK Biobank; MTR, missense tolerance ratio.

Table 3. Summary of supporting genetic evidence from (A) Cardiovascular Disease Knowledge Portal and (B) published GWAS on several cardiovascular outcomes.

From the Cardiovascular Disease Knowledge Portal, we retrieved the most significant common-variant associations (p≤5x10⁻⁸) for cardiovascular, lipid and anthropometric traits at each gene region, clumped by linkage disequilibrium.

Chazara et al.

Figures

Figure 1. Study design.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293350;](https://doi.org/10.1101/2023.07.28.23293350) this version posted August 5, 2023. The copyright holder for this preprint

Chazara et al.

Figure 2. Forest plot of the significant results $(p<2.7x10⁻⁷)$ from the meta-analysis of CHARM, **CORONA and the UK Biobank for time to cardiovascular death (A-E) and time to cardiovascular death and/or hospitalisation for heart failure (F-G).**

A, *FAM221A* in the flexible non-synonymous model; **B**, *CUTC* in the flexible non-synonymous (MTR) model; **C**, *IFIT5* in the flexible damaging model; **D**, *STIMATE* in the flexible nonsynonymous model; **E**, *TAS2R20* in the flexible non-synonymous and/or in flexible non-synonymous (MTR) model; **F**, *CALB2* in the flexible non-synonymous model; **G**, *BLK* in the ultra-rare model.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293350;](https://doi.org/10.1101/2023.07.28.23293350) this version posted August 5, 2023. The copyright holder for this preprint

Chazara et al.

Figure 3. Lollipop plots depicting the individual variants across the candidate genes from the meta-analysis of time to cardiovascular death (A-E) and time to cardiovascular death and/or hospitalisation for heart failure (F-G).

Variants in patients with event at the top and no-event at the bottom. More details on variants identified in heart failure patients with detrimental events in **Supplementary Table 4**. **A**, *FAM221A* in the flexible non-synonymous model (ENST00000344962); **B**, *CUTC* in the flexible nonsynonymous (MTR) model (ENST00000370476); **C**, *IFIT5* in the flexible damaging model (ENST00000371795); **D**, *STIMATE* in the flexible non-synonymous model (ENST00000355083); **E**, *TAS2R20* in the flexible non-synonymous and/or in flexible non-synonymous (MTR) model (ENST00000538986); **F**, *CALB2* in the flexible non-synonymous model (ENST00000302628); **G**, *BLK* in the ultra-rare model (ENST00000259089). Lollipop plots were produced with the cbioportal mutation mapper tool 61,62 .

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.07.28.23293350;](https://doi.org/10.1101/2023.07.28.23293350) this version posted August 5, 2023. The copyright holder for this preprint

Chazara et al.

Figure 4. Heatmaps showing the differential expression in cardiac tissue from patients with heart failure vs controls of candidate genes from the meta-analysis of time to cardiovascular death and time to cardiovascular death and/or hospitalisation for heart failure. The heatmaps show **A**, magnitude of change (logFC; red: upregulated in HF vs control; blue: downregulated in HF vs control), and **B**, significance $(-\log_{10}(a d)$. p-value)). ns: not significant (adj. p >0.05), na: not assessed.

